2019 Chronic or disabling condition (combined)	2019 prev rate
Hypertension  [b2a]	59.00%
Hyperlipidemia  [b2a]	50.00%
Rheumatoid arthritis/Osteoarthritis  [b2a]	35.20%
Ischemic heart disease  [b2a]	27.80%
Diabetes  [b2a]	27.50%
Chronic kidney disease  [b2a]	26.00%
Fibromyalgia, chronic pain, and fatigue  [b2b]	23.10%
Anemia  [b2a]	22.60%
Obesity  [b2b]	21.00%
Depression  [b2a]	19.40%
Anxiety disorders  [b2b]	18.70%
Benign prostatic hyperplasia▲  [b2a]	18.00%
Depressive disorders  [b2b]	17.90%
Cataract  [b2a]	17.60%
Acquired hypothyroidism  [b2a]	16.50%
Heart failure  [b2a]	14.60%
Peripheral vascular disease (PVD)  [b2b]	13.10%
Chronic obstructive pulmonary disease  [b2a]	11.70%
Alzheimer’s disease, related disorders, or senile dementia  [b2a]	11.10%
Tobacco use  [b2b]	9.80%
Glaucoma  [b2a]	9.60%
Atrial fibrillation  [b2a]	8.80%
Cancer, prostate▲  [b2a]	7.60%
Osteoporosis  [b2a]	7.20%
Sensory — deafness and hearing impairment  [b2b]	6.30%
Cancer, female breast‡  [b2a]	6.20%
Asthma  [b2a]	5.20%
Liver disease, cirrhosis and other liver conditions, except hepatitis  [b2b]	5.20%
Pressure and chronic ulcers  [b2b]	4.70%
Alzheimer's disease  [b2a]	3.90%
Stroke/Transient ischemic attack  [b2a]	3.90%
Drug use disorders  [b2b]	3.70%
Bipolar disorder  [b2b]	3.50%
Migraine and chronic headache  [b2b]	3.50%
Mobility impairments  [b2b]	3.00%
Schizophrenia and other psychotic disorders  [b2b]	3.00%
Epilepsy  [b2b]	2.80%
Opioid use disorder  [b2b]	2.40%
Alcohol use disorders  [b2b]	2.10%
Leukemias and lymphomas  [b2b]	1.80%
Schizophrenia  [b2b]	1.80%
Personality disorders  [b2b]	1.50%
Post-traumatic stress disorder (PTSD)  [b2b]	1.40%
Cancer, colorectal  [b2a]	1.20%
Viral hepatitis (general)  [b2b]	1.20%
Viral hepatitis (general)  [b2b]	1.20%
Cancer, lung  [b2a]	1.10%
ADHD, conduct disorders, and hyperkinetic syndrome  [b2b]	1.10%
Intellectual disabilities and related conditions  [b2b]	1.10%
Acute myocardial infarction  [b2a]	1.00%
Cystic fibrosis and other metabolic developmental disorders  [b2b]	1.00%
Spinal cord injury  [b2b]	0.80%
Cancer, endometrial‡  [b2a]	0.70%
Hip/Pelvic fracture  [b2a]	0.70%
Multiple sclerosis and transverse myelitis  [b2b]	0.60%
Sensory — blindness and visual impairment  [b2b]	0.50%
Traumatic brain injury and nonpsychotic mental disorders due to brain damage  [b2b]	0.50%
Cerebral palsy  [b2b]	0.40%
Autism spectrum disorders  [b2b]	0.30%
Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS)  [b2b]	0.30%
Learning disabilities  [b2b]	0.30%
Spina bifida and  other congenital anomalies of the nervous system  [b2b]	0.20%
Cancer, male breast▲  [b2a]	0.10%
Muscular dystrophy  [b2b]	0.10%
Other developmental delays  [b2b]	0.10%
Sickle cell disease  [b2b]	0.04%
b2a Notes
* Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY. The Chronic Conditions Warehouse (CCW) team calculates period prevalence for these rates: beneficiaries with full or nearly full FFS coverage during the year who had claim(s) for the condition within the condition-specified look back period (chronic conditions have a one- to three-year look-back period). Refer to the CCW website for more information, including the algorithms, for these CCW Condition Categories.
** The CCW team may have counted beneficiaries in more than one chronic condition category.
†  Denominator: Includes beneficiaries with full or nearly full FFS coverage (i.e., 11 or 12 months of Medicare Parts A and B [or coverage until time of death] and one month or less of health maintenance organization [HMO] coverage).
‡  Denominator includes only females for cancer, endometrial and female breast.
▲ Denominator includes only males for benign prostatic hyperplasia and cancer, prostate and cancer, male breast. # The CCW team defines the numerator as evidence of claims for the condition.
b2b Notes
* Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY. The Chronic Conditions Warehouse (CCW) team calculates period prevalence for these rates: beneficiaries with full or nearly full FFS coverage during the year who had claim(s) for the condition within the condition-specified lookback period (chronic conditions have a one- to five-year look-back period). Refer to the CCW website for more information, including algorithms, for these other chronic or disabling conditions.
** The CCW team may have counted beneficiaries in more than one chronic condition category.
† Denominator: Includes beneficiaries with full or nearly full FFS coverage (i.e., 11 or 12 months of Medicare Parts A and B [or coverage until time of death] and one month or less of health maintenance organization [HMO] coverage)
‡ The CCW team defines numerator as evidence of claims for the condition
NOTE: The application of different Medicare coverage restrictions/criteria will impact the size of these samples